Edition:
United States

OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

3.84USD
4:00pm EDT
Change (% chg)

$0.08 (+2.13%)
Prev Close
$3.76
Open
$3.79
Day's High
$3.89
Day's Low
$3.70
Volume
95,935
Avg. Vol
114,651
52-wk High
$13.27
52-wk Low
$3.15

Select another date:

Thu, May 4 2017

BRIEF-Oncomed doses first patient with anti-tigit antibody in phase 1 clinical trial

* Oncomed doses first patient with anti-tigit antibody in phase 1 clinical trial

BRIEF-BVF Partners reports 7.9 pct passive stake in Oncomed Pharmaceuticals as of April 17

* BVF Partners LP reports 7.9 pct passive stake in Oncomed Pharmaceuticals as of April 17 - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Oncomed reports workforce reduction

* Oncomed Pharmaceuticals Inc - oncomed will reduce its workforce by approximately 50 percent, resulting in 64 remaining full-time employees

OncoMed's lung cancer drug fails mid-stage study, shares tumble

OncoMed Pharmaceuticals Inc's shares were jolted for a second time in a week after the company said on Monday its experimental lung cancer drug failed a mid-stage study.

UPDATE 2-OncoMed's lung cancer drug fails mid-stage study, shares tumble

* To also discontinue enrollment in colorectal cancer drug trial

BRIEF-Oncomed's Phase 2 trial of Tarextumab in small cell lung cancer does not meet endpoints

* Oncomed's Phase 2 trial of Tarextumab in small cell lung cancer does not meet endpoints

OncoMed's lung cancer drug fails mid-stage study

April 17 OncoMed Pharmaceuticals Inc said on Monday its experimental drug failed a mid-stage study for the treatment of lung cancer.

OncoMed sinks as cancer drug fails; Bayer opts against licensing drugs

(In this April 10th story, corrects paragraphs 1 and 11 to drop the words "stem cell")

CORRECTED-UPDATE 2-OncoMed sinks as cancer drug fails; Bayer opts against licensing drugs

April 10 OncoMed Pharmaceuticals Inc said it would discontinue a trial testing its experimental therapy demcizumab as an initial treatment for advanced pancreatic cancer, after the addition of the drug to standard-of-care failed a mid-stage study.

OncoMed's pancreatic cancer drug fails mid-stage study

April 10 OncoMed Pharmaceuticals Inc said on Monday its experimental drug, in combination with Celgene Corp's Abraxane and chemotherapy, failed a mid-stage study as an initial therapy for advanced pancreatic cancer.

Select another date:

More From Around the Web